Edgewise Therapeutics, Inc. develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy.
Market Cap | 616.809 Million | Shares Outstanding | 63.262 Million | Avg 30-day Volume | 179.61 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -85.172 Million |
Price to Book Value | 1.2832 | Operating Margin | 0.0 | Enterprise Value | 94.031 Million |
Current Ratio | 26.218 | EPS Growth | 0 | Quick Ratio | 25.793 |
1 Yr BETA | 1.3347 | 52-week High/Low | 14.33 / 5.43 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -57.1361 | Altman Z-Score | 14.0663 | Free Cash Flow to Firm | -64.14 Million |
Earnings Report | 2023-08-03 |
Please sign in first
none
13 Thousand total shares from 6 transactions
41.7 Thousand total shares from 6 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
KOCH KEVIN PRESIDENT AND CEO |
|
303,593 | 2023-05-01 | 2 |
MOORE JOHN R GENERAL COUNSEL |
|
6,565 | 2023-05-01 | 10 |
|
9,960 | 2023-05-01 | 2 | |
CARRUTHERS R MICHAEL CHIEF FINANCIAL OFFICER |
|
16,126 | 2023-05-01 | 2 |
DERAKHSHAN BEHRAD CHIEF BUSINESS OFFICER |
|
7,020 | 2023-05-01 | 2 |
RUSSELL ALAN J CHIEF SCIENTIFIC OFFICER |
|
176,191 | 2023-05-01 | 2 |
|
0 | 2023-03-03 | 2 | |
SEMIGRAN MARC CHIEF DEVELOPMENT OFFICER |
|
300,000 | 2022-12-30 | 2 |
|
14,301,551 | 2022-09-16 | 1 | |
|
14,301,551 | 2022-09-16 | 2 | |
|
6,071,703 | 2022-09-14 | 1 | |
|
57,712 | 2022-06-24 | 1 | |
|
42,087 | 2022-06-24 | 1 | |
|
42,087 | 2022-06-24 | 1 | |
|
No longer subject to file | 2021-03-30 | 0 | |
WELLINGTON BIOMEDICAL INNOVATION MASTER INVESTORS (CAYMAN) I L.P. |
|
No longer subject to file | 2021-03-30 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-05-03 18:25:48 -0400 | 2023-05-02 | S | 3,254 | $8.90 | d | 9,960 | direct | 1.7838 | -0.1574 | 3.9874 | 5 | -0.1574 | 6 | |||
2023-05-03 18:25:43 -0400 | 2023-05-02 | S | 3,203 | $8.90 | d | 7,213 | direct | 1.7838 | -0.1574 | 3.9874 | 5 | -0.1574 | 6 | |||
RUSSELL ALAN J - Director - Officer CHIEF SCIENTIFIC OFFICER |
2023-05-03 18:26:08 -0400 | 2023-05-02 | S | 1,602 | $8.90 | d | 176,191 | direct | 1.7838 | -0.1574 | 3.9874 | 5 | -0.1574 | 6 | ||
2023-05-03 18:26:49 -0400 | 2023-05-02 | S | 1,747 | $8.90 | d | 7,020 | direct | 1.7838 | -0.1574 | 3.9874 | 5 | -0.1574 | 6 | |||
2023-05-03 18:26:15 -0400 | 2023-05-02 | S | 1,336 | $8.90 | d | 16,126 | direct | 1.7838 | -0.1574 | 3.9874 | 5 | -0.1574 | 6 | |||
2023-05-03 18:26:36 -0400 | 2023-05-02 | S | 1,897 | $8.90 | d | 6,565 | direct | 1.7838 | -0.1574 | 3.9874 | 5 | -0.1574 | 6 | |||
RUSSELL ALAN J - Director - Officer CHIEF SCIENTIFIC OFFICER |
2023-05-03 18:26:08 -0400 | 2023-05-01 | M | 5,208 | d | 10,417 | direct | |||||||||
RUSSELL ALAN J - Director - Officer CHIEF SCIENTIFIC OFFICER |
2023-05-03 18:26:08 -0400 | 2023-05-01 | M | 5,208 | a | 177,793 | direct | 1.7838 | -0.1574 | 3.9874 | 5 | -0.1574 | 6 | |||
2023-05-03 18:26:15 -0400 | 2023-05-01 | M | 5,208 | d | 10,417 | direct | ||||||||||
2023-05-03 18:26:15 -0400 | 2023-05-01 | M | 5,208 | a | 17,462 | direct | 1.7838 | -0.1574 | 3.9874 | 5 | -0.1574 | 6 | ||||
2023-05-03 18:26:36 -0400 | 2023-05-01 | M | 5,208 | d | 10,417 | direct | ||||||||||
2023-05-03 18:26:36 -0400 | 2023-05-01 | M | 5,208 | a | 8,462 | direct | 1.7838 | -0.1574 | 3.9874 | 5 | -0.1574 | 6 | ||||
2023-05-03 18:26:49 -0400 | 2023-05-01 | M | 5,208 | d | 10,417 | direct | ||||||||||
2023-05-03 18:26:49 -0400 | 2023-05-01 | M | 5,208 | a | 8,767 | direct | 1.7838 | -0.1574 | 3.9874 | 5 | -0.1574 | 6 | ||||
2023-05-03 18:25:43 -0400 | 2023-05-01 | M | 10,416 | d | 20,834 | direct | ||||||||||
2023-05-03 18:25:43 -0400 | 2023-05-01 | M | 10,416 | a | 10,416 | direct | 1.7838 | -0.1574 | 3.9874 | 5 | -0.1574 | 6 | ||||
2023-05-03 18:25:48 -0400 | 2023-05-01 | M | 10,416 | d | 20,834 | direct | ||||||||||
2023-05-03 18:25:48 -0400 | 2023-05-01 | M | 10,416 | a | 13,214 | direct | 1.7838 | -0.1574 | 3.9874 | 5 | -0.1574 | 6 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 22:15:04 UTC | 4.6439 | 0.4161 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 21:45:04 UTC | 4.6439 | 0.4161 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 21:15:03 UTC | 4.6439 | 0.4161 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 20:45:04 UTC | 4.6439 | 0.4161 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 20:15:06 UTC | 4.6439 | 0.4161 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 19:45:04 UTC | 4.6439 | 0.4161 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 19:15:21 UTC | 4.6439 | 0.4161 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 18:45:03 UTC | 4.6439 | 0.4161 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 18:15:04 UTC | 4.6439 | 0.4161 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 17:45:03 UTC | 4.6439 | 0.4161 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 17:15:05 UTC | 4.6439 | 0.4161 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 16:45:04 UTC | 4.6551 | 0.4149 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 16:15:04 UTC | 4.6551 | 0.4149 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 15:45:03 UTC | 4.6551 | 0.4149 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 15:15:04 UTC | 4.6551 | 0.4149 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 14:45:04 UTC | 4.6551 | 0.4149 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 14:15:03 UTC | 4.6551 | 0.4149 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 13:45:04 UTC | 4.6551 | 0.4149 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 13:15:04 UTC | 4.6551 | 0.4149 | 1000000 |
EDGEWISE THERAPEUTICS INC EWTX | 2023-05-31 12:45:04 UTC | 4.6551 | 0.4149 | 1000000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund | EWTX | -700.0 shares, $-4669.0 | 2023-03-31 | N-PORT |